Genedrive® CYP2C19 ID Kit
Guidance for antiplatelet therapy (e.g., clopidogrel) in stroke/ACS patients
CommercialLaunched; active NHS pilot programs
Key Facts
Indication
Guidance for antiplatelet therapy (e.g., clopidogrel) in stroke/ACS patients
Phase
Commercial
Status
Launched; active NHS pilot programs
Company
About Genedrive
Genedrive is a commercial-stage diagnostics company with a mission to deliver rapid, bedside pharmacogenetic testing to enable personalized medicine in time-critical settings. Its core achievement is the successful launch and NHS adoption of its two flagship products: the MT-RNR1 test for neonatal antibiotic safety and the CYP2C19 test for guiding antiplatelet therapy post-stroke. The company's strategy is to leverage its proprietary Genedrive® System platform to expand its test menu, solidify its UK commercial footprint, and pursue international regulatory approvals and partnerships to address a significant global market opportunity in point-of-care genomics.
View full company profile